Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience

Dermatol Ther. 2020 Jul;33(4):e13765. doi: 10.1111/dth.13765. Epub 2020 Jun 30.

Authors

Mariateresa Rossi¹, Chiara Rovati¹, Mariachiara Arisi¹, Simone Soglia¹, Piergiacomo Calzavara-Pinton¹

Affiliation

¹ Dermatology Department, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.

No abstract available

Publication types

Letter

MeSH terms

Adolescent
Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Betacoronavirus*
COVID-19
Coronavirus Infections / epidemiology*
Dermatitis, Atopic / drug therapy*
Dermatitis, Atopic / epidemiology
Female
Humans
Interleukin-4 Receptor alpha Subunit
Italy / epidemiology
Male
Middle Aged
Pandemics*
Pneumonia, Viral / epidemiology*
SARS-CoV-2
Severity of Illness Index
Young Adult

Substances

Antibodies, Monoclonal, Humanized
Interleukin-4 Receptor alpha Subunit
dupilumab